PRESS-RELEASE ·Filed Aug 3, 2026
Press release: earnings
Actionable Insight ▲ Bullish
The $10B acquisition by Vertex at $85/share is the dominant catalyst — the stock should trade near the deal price with minimal spread given expected Q3 2026 close. PALSONIFY's Q2 revenue of $24M (vs $10.3M in Q1) confirms commercial traction but is secondary to the merger. Monitor for regulatory approvals and stockholder vote; any delay risk would widen the arbitrage spread.
Latest settled — T+20d
CRNX ▲ +1.30% at T+20d
LONG call ✓ call won +1.30% · α vs SPY +2.54% · entry $83.86 → $84.95
Latest observation: T+22 -11.75% FF3 residual α
T+1d
+0.17%
call +0.17% · α +0.37%
$84.00
settled 8w ago
T+5d
+0.60%
call +0.60% · α +0.70%
$84.36
settled 8w ago
T+20d
+1.30%
call +1.30% · α +2.54%
$84.95
settled 5w ago
T+60d
—
call — · α —
—
in 25d
Price Chart
Loading chart...
Executive Summary
No summary provided
Key Financial Metrics
EPS
$-1.14
est $-1.18 · +3.4%
Revenue
$25.1M
est $14.9M · +68.6% · +2336.3% YoY
Rating
in line
Key Facts
- Vertex to acquire Crinetics for $85.00/share in cash, total equity value ~$10.0B (~$8.8B net of cash)
- PALSONIFY net product revenue $24.0M in Q2 2026, up from $10.3M in Q1 2026
- FDA granted Rare Pediatric Disease Designation to atumelnant for classic CAH
- Net loss $120.9M in Q2 2026 vs $115.6M in Q2 2025; EPS -$1.14 vs consensus -$1.18
- Cash & investments $1.2B as of June 30, 2026; guidance withdrawn due to pending acquisition
Financial Impact
Acquisition at $85.00/share represents a significant premium to pre-announcement price; PALSONIFY revenue growing rapidly QoQ
revenueepscash
Risk Factors
- Regulatory or stockholder approval failure could collapse the deal
- Competing bid could emerge, though unlikely given unanimous board approval
- Deal closing delayed beyond Q3 2026 guidance
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3337865 |
15 reports for CRNX
75% Hit rate best @ T+20▲ +138.24%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 15-12G | — | awaiting T+1 | — | — |
Sep 1, 2026 4w ago | 25-NSE | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Sep 1, 2026 4w ago | 8-K | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Aug 14, 2026 7w ago | 8-K | $84.70 $84.75 | ▲ +0.06% | ▲ +0.53% | — |
Aug 3, 2026 8w ago | Press Release | $83.86 $84.00 | ▲ +0.17% | ▲ +0.37% | — |
Jul 10, 2026 12w ago | DEFA14A | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jul 10, 2026 12w ago | 8-K | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jun 30, 2026 13w ago | Press Release | $38.68 $42.23 | ▲ +9.18% | ▲ +9.31% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
Showing 10 of 15
US Market Status
Market Closed — Opens Mon (38h 37m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access